Selected Recent Articles
- Monthly Dosing Drug Raises Hopes and Concerns. (July 2016, MedPage Today)
- Long-acting injectable drugs work well for HIV maintenance therapy. (July 2016, AIDSmap)
- What we’re learning about new PrEP drugs and delivery methods at AIDS 2016. (July 2016, Beta Blog)
- Long-acting agents may increase number of patients on therapy, bring new people into care. (July 2016, Healio)
- Five Exciting HIV Prevention Studies We’re Paying Attention to. (June 2016, Beta Blog)
- Weekly PRO 140 Antibody Injections Successfully Combat HIV in Some. (June 2016, Poz); related coverage from AIDSmap
- Injectable antiretrovirals: The future of HIV management? (June 2016, Healio)
- $75K Campbell Grant to Study Long-Acting Treatment That Targets HIV Reservoirs. (May 2016, Poz)
- Studies Begin to Test Long-Acting Antibody Infusions for HIV Prevention. (April 2016, Poz); related coverage from NIAID
- Advances reported in long-acting PrEP. (April 2016, Project Inform)
- Long-acting oral antiretroviral MK-8591 could represent ‘paradigm shift’ in HIV treatment and prophylaxis. (April 2016, AIDSmap)
- Men Are Not Macaques and Other Lessons from Long-Acting PrEP Study. (March 2016, TheBodyPro)
- Injectable Long-Acting Isentress as PrEP Protects Mice Against Vaginal HIV Exposure. (March 2016, Poz)
- New NRTI MK-8591 (EFdA): weekly oral dosing and once-yearly slow-release dosing has potential for HIV treatment and PrEP. (March 2016, HIV Treatment Bulletin)
- Injectable long-acting cabotegravir shows promise as PrEP in early safety trial (February 2016, Poz); related coverage from AIDSmap and abstract from 2016 Retrovirus Conference
- Long-acting injectable cabotegravir + rilpivirine works well as HIV maintenance therapy. (February 2016, AIDSmap); related coverage from Poz and TheBody
- What is a drug “tail,” and what does it have to do with long-acting PrEP? (February 2016, Beta Blog)
- What’s on the horizon? New PrEP options presented at Retrovirus Conference 2016. (February 2016, Beta Blog)
- IV and Injectable HIV Treatments Are Much Discussed – But Won’t Be Here Anytime Soon. (January 2016, Journal Watch)
- ViiV and Janssen Secure Plans to Develop Long-Acting HIV Treatment. (January 2016, Poz)
- Four- and Eight-Week HIV Treatments Show Promise. (November 2015, Poz)
- Weekly Injectable HIV Antibody Treatment Shows Promise. (August 2015, Poz)
- An Update on the Pipeline of Antibodies, Long-Acting Antiretrovirals and Vaccines. (August 2015, AVAC)
- PrEP-Delivering Subdermal Implant Shows Promise in Animal Study. (May 2015, Poz)
- Injectable PrEP: The Next Order of the Day. (May 2015, Beta Blog)
- Effective Two-Drug HIV Regimen Sets Stage for Long-Acting Treatment. (April 2015, Poz)
- Primate Studies Raise Hope of Eventual Quarterly Injected PrEP. (January 2015, Poz)
- Injectable rilpivirine shows promise in phase I trials – but may work better for anal than vaginal sex. (November 2014, AIDSmap)
- Injectable cabotegravir makes progress towards human efficacy studies: doubts about injectable rilpivirine. (October 2014, AIDSmap)
- Long-Acting, Investigational Integrase Inhibitor Cabotegravir Shows Promise. (October 2014, TheBody)
- Long-Acting HIV Drugs for Maintenance and PrEP. (March 2014, Beta Blog)
- Early Trial Paves the Way for Study of Long-Acting HIV Meds. (March 2014, Poz)
- Novel two-drug maintenance combination works at least as well as triple therapy: stage set for long-lasting injectable formulation. (March 2014, AIDSmap)
- Trial Bodes Well for Long-Acting HIV Drugs. (March 2014, MedPage Today)
- Early Trial Raises Hopes of Quarterly PrEP Injections. (March 2014, Poz)
- Monkey studies confirm viability of injectable PrEP drug. (March 2014, AIDSmap)
- Monthly PrEP Injections Show Promise in Female Monkeys. (March 2014, Poz)
- Long-Acting HIV Drugs Could Extend Lives of Low Adherers. (November 2013, Poz)
- Long-acting antiretrovirals may improve survival for people with poor adherence. (October 2013, AIDSmap)
- Long-Acting HIV Antiretrovirals May Be Revolutionary. But Will They Be Worth It? (October 2013, TheBodyPro)
- Once-a-Month HIV Meds Show Promise in Early Trial. (July 2013, Poz)
- Long-acting GSK1265744 and TMC278-LA appear safe and practical in early study. (July 2013, AIDSmap)
- PrEP GSK744 Integrase Administered Monthly Perhaps Quarterly Prevents HIV-Infection in Monkeys. (March 2013, NATAP)
- Monthly injectable drug offers 100% protection against HIV in monkeys – could be dosed every three months. (March 2013, AIDSmap)